// App-Quantinova.ai

5028 : Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC): Detailed analyses from the phase 3 LATITUDE trial.

Researchers

Presenter

  • Kim N. Chi

Principal Investigators

  • Namphuong Tran

  • Susan Feyerabend

  • Nobuaki Matsubara

  • Mustafa Ozguroglu

  • Luis Enrique Fein

  • Alfredo Rodriguez Antolin

  • Boris Yakovlevich Alekseev

  • Giri Sulur

  • Andrew Protheroe

  • Peter De Porre

  • Susan Li

  • Youn C. Park

  • Suneel Mundle

  • Karim Fizazi

Medical Centers

  • BC Cancer - Vancouver Centre, Vancouver, BC, Canada

  • Janssen Research & Development, Los Angeles, CA

  • Studienpraxis Urologie, Nurtingen, Germany

  • National Cancer Center Hospital, Tokyo, Japan

  • Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

  • Instituto de Oncologia de Rosario, Rosario, Argentina

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Janssen Research & Development, Beerse, Belgium

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, LLC, Raritan, NJ

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

Locations

  • Canada

  • Japan

  • Argentina

  • Germany

  • Turkey

  • Spain

  • United Kingdom

  • United States

  • France

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Prednisone

Outcome

  • Unknown

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01715285

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved